Skip to content
香港聯合腫瘤中心
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En

Category: 標靶治療

Phase 3 randomized, double-blind study in first-line ER+ (≥1%), HER2− advanced/metastatic breast cancer comparing palazestrant + ribociclib vs letrozole + ribociclib. Includes key inclusion/exclusion criteria and dosing details. Contact Hong Kong United Oncology Centre.

NCT07085767: OPERA-02 Study

The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced/metastatic breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the eligibility criteria for this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
December 18, 2025 No Comments
第四期肺癌康復奇蹟｜鍾喜英HER2基因突變成功治療個案 - 李宇聰醫生解析基因檢測重要性

Stage 4 Lung Cancer Recovery Miracle | A Successful Treatment Case of HER2 Gene Mutation

Ms. Zhong Xiying was diagnosed with multiple metastases of stage 4 lung cancer in the brain, liver and bone, and once wanted to give up treatment. Dr. Li Yu Chung, Jacky insisted on genetic testing to find rare HER2 mutations, and quickly formulated a personalized targeted treatment plan to successfully control the condition. Real cases share how genetic testing has changed destiny, and now Ms. Zhong can travel with her family and enjoy happiness. The United Cancer Centre of Hong Kong provides comprehensive genetic testing and personalized treatment services.

立即閱讀
December 3, 2025 No Comments

NCT06966700: Trofuse-032/MK2870-032 Research

Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with high-risk early-stage triple-negative breast cancer (TNBC) or hormone receptor-weak positive/HER2-negative breast cancer, please contact us. We will conduct an initial assessment to determine if you meet the criteria for participation in this clinical trial. Medication and imaging scan costs are fully covered. However, patients must understand the purpose of the study and the potential risks involved.

立即閱讀
November 19, 2025 No Comments
DURIGAST試驗FD組與FDT組療效對比數據表格，顯示4個月無進展生存率、中位PFS、客觀緩解率、中位OS及1年以上疾病控制率

Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer

The third phase of the ADRIATIC study showed that Durvalumab consolidation therapy significantly extended the survival of patients with limited-stage small cell lung cancer (SCLC), with a median total survival of 56 months, which was significantly improved compared to 33 months in the placebo group. This article introduces the research data, clinical significance and treatment prospects in detail to help you understand the latest advances in immunotherapy for lung cancer.

立即閱讀
September 26, 2025 No Comments
Tovorafenib為攜帶BRAF基因變異的兒童低級別膠質瘤患者提供突破性治療

Tovorafenib approved by the FDA: breakthrough treatment for low-grade glioma in children with BRAF mutation

The FDA accelerated the approval of Tovorafenib (Ojemda) for the treatment of low-grade gliomas in children with recurrent or refractory BRAF variants on April 23, 2024. This article introduces its efficacy data, safety characteristics and clinical application guidelines in detail. It is suitable for reference by parents and medical staff who are concerned about the treatment of brain tumors in children. Learn more about the latest information about this breakthrough targeted therapy.

立即閱讀
September 26, 2025 No Comments
Revumenib治療急性白血病療效數據

A new generation of Menin inhibitors revolutionizes the treatment of acute leukemia, giving Hong Kong patients new hope

The 2024 Annual meeting of the American Society of Hematology will reveal the safety and efficacy of a new generation of Menin inhibitors in the treatment of acute myeloid leukemia (AML). Drugs such as Ziftomenib and Bleximenib showed significant complete remission rates for KMT2A rearrangement and NPM1 mutations, bringing new hope to patients in Hong Kong. Learn more about clinical trial data and treatment prospects.

立即閱讀
September 23, 2025 No Comments
Zenocutuzumab 用於治療 NRG1 基因融合癌症的臨床研究成果。

Zenocutuzumab: FDA approves new bispecific antibody for the treatment of NRG1 gene fusion cancer

Zenocutuzumab was approved by the U.S. FDA for the treatment of patients with lung cancer and pancreatic cancer with NRG1 gene fusion, marking a breakthrough in cancer treatment.

立即閱讀
September 19, 2025 No Comments
Vorasidenib IDH1/2抑制劑分子結構，用於治療IDH突變型星形細胞瘤及少突膠質細胞瘤

The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma

The U.S. FDA approved the IDH1/2 inhibitor Vorasidenib for use in patients with specific astrocytoma and oligodendrocytoma in August 2024. The INDIGO clinical trial has shown that it significantly prolongs the survival period without progress, bringing new treatment options to patients with IDH mutant glioma. Learn about applicable patients, medication recommendations, and safety information.

立即閱讀
September 17, 2025 No Comments
DURIGAST試驗FD組與FDT組療效對比數據表格，顯示4個月無進展生存率、中位PFS、客觀緩解率、中位OS及1年以上疾病控制率

Immunotherapy combined with chemotherapy for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma: Analysis of the results of DURIGAST PHASE II trial

研究概況 法國多中心非對照II期臨床試驗（PRODIGE 59-FFCD 1707-DURIGAST）評估了FOLFIRI方案聯合PD-L1抑制劑du

立即閱讀
September 15, 2025 No Comments
Tovorafenib為攜帶BRAF基因變異的兒童低級別膠質瘤患者提供突破性治療

FDA accelerated approval of Tovorafenib for the treatment of low-grade glioma patients with recurrent or refractory BRAF gene variants in children

The FDA accelerated the approval of the RAF inhibitor Tovorafenib (Ojemda) in April 2024 for the treatment of patients with recurrent/refractory low-grade glioma in children carrying BRAF gene variants. THE FIREFLY-1 study SHOWED A TOTAL REMISSION RATE OF 51% AND A MEDIAN REMISSION DURATION OF 13.8 MONTHS, PROVIDING THE FIRST BRAF TARGETED TREATMENT OPTION FOR CHILDREN WITH BRAIN TUMORS. The United Cancer Centre of Hong Kong provides professional child cancer consultation.

立即閱讀
September 13, 2025 No Comments
Page1 Page2 Page3 Page4 Page5
香港聯合腫瘤中心

The Hong Kong United Oncology Centre (HKUOC) provides cancer-related medical services such as cancer screening, cancer diagnosis and cancer treatment, including immunotherapy, chemotherapy, targeted drug therapy, radiation therapy, hormone therapy and palliative care.

Contact us

  • Address: Rooms 01-06, 20/F, 238 Nathan Road, Kowloon (MTR Jordan Station Exit E)
  • Phone: +852 2386 8002
  • WhatsApp：5518 2992
  • Fax: (852) 2386 8229
  • Macau: Enquiry@hkuoc.hk

Consultation time

Monday to Friday

9:00 am to 1:00 pm

2:00 p.m. to 6:00 p.m.

Saturday

9:00 am to 1:00 pm

Closed on Sundays and public holidays

Types of cancer

  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer
  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer

Cancer treatment

  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy
  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy

phone

WhatsApp

Facebook